Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 22Stomach Neoplasms 20Carcinoma, Non-Small-Cell Lung 16Colorectal Neoplasms 9Nasopharyngeal Carcinoma 5Lung Neoplasms 5Esophageal Squamous Cell Carcinoma 5Small Cell Lung Carcinoma 4Neoplasms 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Lymphoma, Extranodal NK-T-Cell 3Liver Neoplasms 3Cholangiocarcinoma 3Carcinoma, Renal Cell 3Carcinoma 3Nonsquamous Non-Small Cell Lung Cancer 2Nasopharyngeal Neoplasms 2Esophageal Neoplasms 2Carcinoma, Neuroendocrine 2Advanced Biliary Tract Cancer 2Unresectable Locally Advanced Pancreatic Cancer 1Triple Negative Breast Neoplasms 1Tislelizumab 1Thoracic Neoplasms 1Thoracic Malignancies 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Respiratory Tract Diseases 1Recurrent/ Advanced Stage Endometrial Cancer Patients 1

Interventions

Gemcitabine 9Oxaliplatin 6Cisplatin 6Capecitabine 6durvalumab 4apatinib 4S 1 (combination) 4Irinotecan 4Immune Checkpoint Inhibitors 4surufatinib 3Injections 3Drug Therapy 3pembrolizumab 2lenvatinib 2camrelizumab 2Taxes 2Leucovorin 2Fluorouracil 2Docetaxel 2130-nm albumin-bound paclitaxel 2tremelimumab 1toripalimab 1taxane 1spartalizumab 1sintilimab 1regorafenib 1manganese chloride 1irinotecan sucrosofate 1gimeracil 1gemcitabine-oxaliplatin regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Biliary Tract Neoplasms × sintilimab × Clear all
NCT04300959 2020-03-09

Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer

Zhejiang Cancer Hospital

Phase 2 Unknown
80 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡